Materials Healthcare Sector

Amarin

Market Cap: US$230.1m

A pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally.

Acelyrin

Market Cap: US$229.2m

A clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines.

Cipher Pharmaceuticals

Market Cap: CA$317.1m

Operates as a specialty pharmaceutical company in Canada.

Solid Biosciences

Market Cap: US$228.7m

Develops therapies for neuromuscular and cardiac diseases in the United States.

Optima Health

Market Cap: UK£170.0m

Provides occupational health and wellbeing services for the public and private sectors in the United Kingdom.

Bright Minds Biosciences

Market Cap: CA$313.2m

A biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States.

Fennec Pharmaceuticals

Market Cap: US$225.6m

Operates as a commercial stage biopharmaceutical company in the United States.

MediWound

Market Cap: US$225.6m

A biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally.

Monopar Therapeutics

Market Cap: US$225.6m

A clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.

Tango Therapeutics

Market Cap: US$224.4m

A precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.

AirSculpt Technologies

Market Cap: US$223.7m

Focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States, Canada, and the United Kingdom.

OptimizeRx

Market Cap: US$221.0m

Operates as a digital healthcare technology company.

Dimerix

Market Cap: AU$342.3m

A biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia.

Medical Facilities

Market Cap: CA$301.1m

Through its subsidiaries, owns and operates specialty surgical hospitals and ambulatory surgery center in the United States.

enGene Holdings

Market Cap: US$214.1m

Through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer.

Kodiak Sciences

Market Cap: US$213.7m

A clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.

Tevogen Bio Holdings

Market Cap: US$213.3m

A clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders.

ADC Therapeutics

Market Cap: US$213.2m

Provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

Perspective Therapeutics

Market Cap: US$210.1m

Develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.

Performant Healthcare

Market Cap: US$209.9m

Provides audit, recovery, and analytics services in the United States.

OraSure Technologies

Market Cap: US$209.4m

Develops, manufactures, markets, sells, and distributes diagnostic products, specimen collection devices, and other diagnostic products in the United States, Europe, Africa, and internationally.

Integrated Diagnostics Holdings

Market Cap: US$209.3m

Operates as a consumer healthcare company that provides medical diagnostics services to patients.

Design Therapeutics

Market Cap: US$208.3m

A clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.

Actuate Therapeutics

Market Cap: US$207.0m

A clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States.

VitaSpring Biomedical

Market Cap: US$207.0m

Focuses on the development of drugs of cell medicine.

Lexicon Pharmaceuticals

Market Cap: US$207.0m

A biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease.

Cardiff Oncology

Market Cap: US$204.2m

A clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers.

Codexis

Market Cap: US$203.0m

Provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China.

BioStem Technologies

Market Cap: US$200.8m

A life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services.

Bioventix

Market Cap: UK£148.9m

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide.

Born

Market Cap: US$197.4m

Does not have significant operations.

biote

Market Cap: US$195.1m

Operates in practice-building business within the hormone optimization space.

ME Therapeutics Holdings

Market Cap: CA$269.8m

A preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology.

Quanterix

Market Cap: US$193.8m

A life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions.

Monash IVF Group

Market Cap: AU$300.0m

Provides assisted reproductive and specialist women imaging services in Australia and Malaysia.

4basebio

Market Cap: UK£144.1m

Engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally.